Pharmacoeconomic evaluation of the use of the drug Reagila (cariprazine) for the treatment of patients with schizophrenia with negative symptoms

The object of the study is the pharmacoeconomic acceptability of using new atypical antipsychotic
cariprazine in patients with schizophrenia with negative symptoms in the health system of the
Republic of Belarus.
A systematic review of data on the use of atypical antipsychotics in patients with schizophrenia with
negative symptoms in available literature and electronic databases has been performed. Based on
a systematic study, taking into account the nomenclature of medicines registered in the Republic of
Belarus, the list of medical procedures and interventions that comply with the clinical protocols for
the diagnosis and treatment of patients with mental and behavioral disorders, a pharmacoeconomic
analysis of the use of atypical antipsychotics (cariprazine, risperidone, olanzapine, quetiapine ) in
the conditions of the healthcare system of the Republic of Belarus using the analysis "cost of illness"
and "costs/effi ciency". Pharmacoeconomic models of the use of atypical antipsychotics (cariprazine,
risperidone, olanzapine, quetiapine) in patients with schizophrenia have been developed, where the
number of patients adhered to treatment has been used as an indicator of eff ectiveness. For patients
with schizophrenia with negative symptoms, a model has been developed that takes into account,
as an indicator of eff ectiveness, the percentage of patients who have achieved improvement in
negative symptoms by 20% and 30% on the PANSS-FSNS scale. A one-way deterministic sensitivity
analysis was carried out with the inclusion of cost parameters of cariprazine. No discounting was
made. The target population of patients suff ering from schizophrenia with negative symptoms and
requiring the administration of "Reagila®" (cariprazine) was calculated. The analysis of the "impact
on the budget."
Clinical and economic analysis showed the feasibility of using cariprazine:
 for a cohort of patients with schizophrenia compared with atypical antipsychotics (olanzapine,
quetiapine, risperidone in the form of an oral solution) based on the calculated cost-eff ectiveness
ratio of one compliant patient;
 for the cohort of patients suff ering from schizophrenia with negative symptoms compared with
risperidone (oral solution) based on the results of the cost-eff ectiveness analysis, where as the
number of patients who achieved an improvement in negative symptoms by 20% and 30%
according to the PANSS-FSNS scale was taken as an indicator of eff ectiveness.